Polycythemia Vera Treatment Market Share

North America Market Forecast:

North America industry is likely to dominate majority revenue share of 34% by 2037. The growth of this market can be attributed to various factors such as high demand for novel drug delivery system, the development of advanced medication, and increasing investment in research and development activities. Rogeinterferon alfa-2b-njft is being sought for the treatment of polycythemia vera (PV), and in May 2021, PharmaEssentia USA Corporation announced the resubmission of their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).

Europe Market Statistics

The polycythemia vera treatment market in the Europe is set to grow significantly during the estimated period. The increasing enhancement in diagnostic testing in the Europe region is poised to drive the growth of polycythemia vera treatment sector in the region.